Ton N. Schumacher

Immunology · 2000–2022

A researcher in the Science corpus: 22 papers; trusts 18 researchers and is trusted by 6 researchers here, as inferred from the citation graph.

Subfields

Immunology — 488 citations into it; #841 of 2,160 by trust here, #96 by citations
Oncology — 450 citations into it; #697 of 1,698 by trust here, #45 by citations

Whom Ton N. Schumacher trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Who trusts Ton N. Schumacher overall

Papers from Ton N. Schumacher's perspective

Ordered by how strongly the researchers Ton N. Schumacher trusts endorse each paper. Same corpus, a different order for every researcher.

Molecular signature of CD8+ T cell exhaustion during chronic viral infection. (Immunity)
T cell exhaustion (Nature Immunology)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (Journal of Experimental Medicine)
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (Molecular and Cellular Biology)
Coregulation of CD8+ T cell exhaustion during chronic viral infection by multiple inhibitory receptors (Nature Immunology)
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
Cancer immunoediting: from immunosurveillance to tumor escape (Nature Immunology)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression (Nature)
Tertiary lymphoid structures in the era of cancer immunotherapy (Nature Reviews. Cancer)

Their papers

Signatures of mutational processes in human cancer (2013) — 9,146 citations
Tertiary lymphoid structures in cancer (2022) — 937 citations
CD8+ T cell states in human cancer: insights from single-cell analysis (2020) — 1,185 citations
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers (2020) — 1,218 citations
B cells and tertiary lymphoid structures promote immunotherapy response (2020) — 2,250 citations
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial (2019) — 793 citations
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (2018) — 786 citations
T Cell Dysfunction in Cancer (2018) — 1,105 citations
Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids (2018) — 973 citations
Regulation and Function of the PD-L1 Checkpoint (2018) — 1,861 citations
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade (2018) — 1,018 citations
Dysfunctional CD8+ T cells form a proliferative, dynamically regulated compartment within human melanoma (2018) — 1,027 citations
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators (2017) — 631 citations
Guidelines for the use of flow cytometry and cell sorting in immunological studies (2017) — 1,146 citations
The “cancer immunogram” (2016) — 596 citations
Neoantigens in cancer immunotherapy (2015) — 4,352 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (2015) — 6,586 citations
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma (2014) — 654 citations
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) — 1,894 citations
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma (2013) — 827 citations